TY - JOUR
T1 - Susceptibilities of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2012
AU - Yamaguchi, Keizo
AU - Ishii, Yoshikazu
AU - Tateda, Kazuhiro
AU - Shimizu, Chikara
AU - Suwabe, Akira
AU - Kaku, Mitsuo
AU - Hishinuma, Akira
AU - Maesaki, Shigefumi
AU - Murata, Mitsuru
AU - Matsumoto, Tetsuya
AU - Murakami, Hinako
AU - Otsuka, Yoshihito
AU - Maekawa, Masato
AU - Yagi, Tetsuya
AU - Yamagishi, Yuka
AU - Fujita, Shinichi
AU - Hida, Yukio
AU - Nakatani, Kaname
AU - Ichiyama, Satoshi
AU - Fujimoto, Ikuko
AU - Kohno, Hisashi
AU - Okuda, Kazuyuki
AU - Kusano, Nobuchika
AU - Kurokawa, Yukinori
AU - Watanabe, Yaeko
AU - Negayama, Kiyoshi
AU - Miyamoto, Hitoshi
AU - Kiyosuke, Makiko
AU - Mashiba, Kouichi
AU - Yanagihara, Katsunori
AU - Aoki, Yosuke
AU - Hiramatsu, Kazufumi
PY - 2016/7
Y1 - 2016/7
N2 - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.
AB - Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin (TAZ/PIPC) in 3,952 bacterial strains isolated in 2012 were conducted in Japan. β-lactamase production was investigated in over 80% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Providencia spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group. Extended spectrum β-lactamase-producing strains in E. coli, K. pneumoniae and P. mirabilis were 19.0%, 7.2% and 8.2%, respectively. Metallo-β-lactamase producers in P. aeruginosa and Acinetobacter spp. were 1.0% and 0.4%, respectively, and no strain of E. cloacae and S. marcescens was detected. Susceptibility of 3,952 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute or European Committee on Antimicrobial Susceptibility testing were distributed from 79.2% in E.cloacae to 100% in methicillin-susceptible S. aureus, coagulase-negative staphylococci, M. catarrhalis, P. mirabilis, indole-positive Proteus spp. and H. influenzae including β-lactamase-negative ampicillin-resistant strains. When compared with those in previous investigations conducted in 2010, the susceptibility to TAZ/PIPC had not changed. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for infectious diseases.
KW - CLSI
KW - EUCAST
KW - Susceptibility
KW - Tazobactam/piperacillin
KW - β-lactamase
UR - http://www.scopus.com/inward/record.url?scp=84982293231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982293231&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84982293231
SN - 1340-7007
VL - 64
SP - 668
EP - 680
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
IS - 4
ER -
